BioNJ Media Advisory: U.S. Labor Department Assistant Secretary to Visit as Chromocell Marks 100th Employee

--(BUSINESS WIRE)--

Date:

 

Thursday, February 9, 2012

 

Time:

1:00 to 2:00 p.m.

 

Location:

Chromocell Corporation

685 U.S. Highway One
North Brunswick, NJ 08902

CLICK HERE for directions

 

What:

U.S. Assistant Secretary of Labor for Employment and Training Joan Oates, will tour the emerging biotechnology company Chromocell Corporation in North Brunswick, NJ to discuss employee training programs as it celebrate the hiring of its 100th employee. Although the company’s personnel are highly educated, Chromocell is taking advantage of training grants offered by the New Jersey Department of Labor and Workforce Development via the New Jersey Community College Consortium for Workforce and Economic Development and BioNJ to keep its employees up-to-date with the latest technologies and practices in the highly competitive global biotechnology industry.

 

Participants:

Jane Oates, Assistant Secretary of Labor Employment and Training, U.S. Department of Labor

Harold Wirths, NJ Commissioner of Labor and Workforce Development
Caren Franzini, CEO of the New Jersey Economic Development Authority
Joann La Perla-Morales, President of Middlesex County College
Christian Kopfli, Esq., Chief Executive Officer, Chromocell Corporation
Debbie Hart, President of BioNJ (Confirmed)
 

Background:

An emerging biotechnology company, Chromocell Corporation of North Brunswick, NJ is creating the type of jobs that are needed to keep New Jersey and the nation in the forefront of medical innovation. The company, which started with three employees in 2002, recently marked the hiring of its 100th employee and plans further hiring.

 
Although the company’s employees are highly educated, Chromocell is taking advantage of training grants for employees offered by the New Jersey Department of Labor and Workforce Development via the New Jersey Community College Consortium for Workforce and Economic Development and BioNJ. Many of the classes have been provided by Middlesex Community College.
 
Founded in 2002, Chromocell is a biotechnology company focused on the discovery and development of flavors and nutritional ingredients, and therapeutics through its pioneering Chromovert technology, which uses naturally occurring cells and receptors in high performance discovery platforms.
 
The company resides in laboratory and office space at the New Jersey Economic Development Authority’s (EDA) Commercialization Center for Innovative Technologies in North Brunswick, NJ. The company started in the incubator section and expanded in March of 2011 to a “tweener” facility to accommodate the growing needs of the company’s programs, particularly in the areas of medicinal and natural products chemistry.
 
The New Jersey Community College Consortium for Workforce and Economic Development brings together the vast resources of the 19 New Jersey community colleges for New Jersey companies and organizations to access, develop, and receive workforce education and training for their current and emerging workforce statewide.
 

BioNJ is the trade association for New Jersey’s thriving biotechnology industry, which has grown from 80 companies in 1998 to now more than 335 companies. BioNJ represents companies engaged in biopharmaceutical, biomedical, bioagricultural and bioremedial endeavors.



CONTACT:

BioNJ
Bill O’Donnell
Director of Public Affairs
(O) 609-890-3185
(C) 609-802-3091
[email protected]

KEYWORDS:   United States  North America  New Jersey

INDUSTRY KEYWORDS:   Education  Continuing  Health  Biotechnology  Training  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.